PERK promotes immunosuppressive M2 macrophage phenotype by metabolic reprogramming and epigenetic modifications through the PERK-ATF4-PSAT1 axis

Uday P. Pratap1,2, Ratna K. Vadlamudi1,2,3,*

Abstract
The endoplasmic reticulum (ER) is a specialized organelle that participates in multiple cellular functions including protein folding, maturation, trafficking, and degradation to maintain homeostasis. However, hostile conditions in the tumor microenvironment (TME) disturb ER homeostasis. To overcome these conditions, cells activate ER stress response pathways, which are shown to augment the suppressive phenotypes of immune cells; however, the molecular mechanisms underpinning this process remain elusive. Here, we discuss a recent study by Raines et al, that suggests the role of the helper T-cell 2 (TH2) cytokine interleukin-4 (IL-4), and the TME in facilitating a protein kinase RNA-like ER kinase (PERK)-signaling cascade in macrophages, which promotes immunosuppressive M2 macrophage activation and proliferation. Further, the authors showed that PERK signaling promotes both mitochondrial respirations to fulfill cellular energy requirements and signaling through ATF4, which regulate phosphoserine aminotransferase 1 (PSAT1) activity to mediate the serine biosynthesis pathway. These results highlight a previously uncharacterized role for PERK in cellular metabolism and epigenetic modification in M2 macrophages, and thus offers a new therapeutic strategy for overcoming the immunosuppressive effects in the TME.

Keywords: endoplasmic reticulum, ER stress, protein kinase RNA-like ER kinase, M2 macrophage, tumor-associated macrophages, myeloid cell-derived suppressor cells

Cancer cells have a high growth rate; therefore, they have sustained and enhanced demand for de novo protein synthesis, folding, and maturation. Hostile environmental conditions such as hypoxia, oxidative stress, and chemotherapy jeopardize the fidelity of protein folding in the endoplasmic reticulum (ER), resulting in ER stress (ERS) [1]. In mammalian cells, the unfolded protein response (UPR) is initiated by three ER transmembrane proteins which act as a sensors of ER stress: inositol-requiring enzyme 1α (IRE1α), activating transcription factor 6 (ATF6), and protein kinase RNA-like ER kinase (PERK) [2]. However, persistent ER stress is associated with the adaptation of malignant cells in the TME and can disturb ER homeostasis in cancer and immune cells. An earlier study showed that the IRE1α arm of UPR signaling is crucial for macrophage polarization and dysregulation of the immune system in the TME [3]. Nonetheless, function of other arms of UPR signaling in the regulation of macrophage metabolism and in the acquisition of immunosuppressive functions remain elusive.

Macrophages are key component of innate immune system and play a crucial role in maintaining tissue homeostasis and immunity [4]. Macrophages can be further categorized as M0 (naive), M1 macrophages (proinflammatory), and M2 macrophages (immunosuppressive) [5]. A recent study published in Nature Immunology discovered the PERK arm of UPR signaling augments the metabolic functions of macrophages and promotes an immunosuppressive M2 macrophage phenotype [6]. In this study, the authors showed that tumor-associated macrophages (TAMs) isolated from lung carcinoma upregulates the PERK arm of the ER stress pathway. To gain mechanistic insights, the authors stimulated bone marrow-derived macrophages (BMDMs) isolated from mouse with lipopolysaccharide (LPS) + interferon-gamma (IFN-γ, M1 macrophage) and IL-4 (M2 macrophage) cytokines and performed RNA-seq analysis. Results indicated that macrophages stimulated with IL-4 (M2) has a high level of PERK in comparison to macrophages activated with LPS + IFN-γ (M1), which exhibited low levels of PERK activation. To further validate the role of PERK signaling in immunosuppressive M2 macrophages, the authors used myeloid-specific conditional knockout mice (PERK<sup>−<sup>−</sup></sup>) and showed that activation of PERK signaling promotes immunosuppressive M2 macrophages, however, deletion of PERK attenuated this effect as well as restores the antitumor immune response [6].

Metabolic reprogramming of TAMs is very dynamic process and is influenced by the nutrient requirements of cancer cells, demands of tumor progression, and the course of chemotherapy. Interestingly, unbiased RNA-seq analysis of M2 macrophages from wild-type (WT) and PERK<sup>−<sup>−</sup></sup> mice revealed that deletion of PERK downregulates the expression of several key genes responsible for lipid metabolism and mitochondrial respiration including lysosomal acid lipase (LIPA), peroxisome proliferator-activated receptor γ (PPAR-γ), and PPAR-γ coactivator-1β (PGC-1β), leading to a significant decreases in lipid intake, lipolysis, and energy intake in M2 macrophages [6]. Another study showed that PERK signaling regulate mitochondrial autophagy by mitochondrial reprogramming and epigenetic changes in immune cells [7]. To validate the PERK mediated regulation of mitochondria function, Raines et al performed transmission
electron microscopy in M2 macrophages isolated from WT and \( \text{PERK} \text{cKO} \) mice. \( \text{PERK} \text{cKO} \) M2 macrophages exhibited disorganized mitochondria cristae and lower mitochondrial numbers in comparison to WT M2 macrophages \([6]\). Collectively, these results suggest that \( \text{PERK} \) signaling dysregulates M2 macrophage mitochondrial homeostasis.

Availability of serine, a nonessential amino acid is very essential to maintain mitochondrial homeostasis and function. Utilizing metabolomics approach, it was shown that serine derived lipids are very essential to support mitochondrial metabolism and that serine deprivation leads to mitochondrial fragmentation and alters mitochondrial fatty acid metabolism \([8]\). Interestingly in this study, using metabolite profiling the authors found that the levels of intracellular 3-phosphoglycerate, serine, and glycine were significantly elevated in IL-4 stimulated M2 macrophage compared to M1 macrophages. \( \text{PERK} \) deletion contributed to a decrease in serine levels as well as downregulated serine synthesis pathway gene \( \text{psat1} \). Further, using myeloid cell conditional \( \text{Psat1} \) knockout (PSAT1\text{cKO}) mice, Raines et al demonstrated that serine metabolism is necessary for immunosuppressive M2 macrophage phenotype \([6]\).

Coculture of phosphoserine aminotransferase 1 (PSAT1\text{cKO}) BMDMs with melanoma or lung cancer cell lines showed a significant diminution of the suppressive M2 macrophage phenotype suggesting that serine biosynthesis promotes the immunosuppressive M2 phenotype via the PERK-ATF4 pathway. Furthermore, the authors showed that \( \text{PERK} \) deletion resulted in alteration in \( \alpha \)-KG production, and it was further dysregulated in PSAT1\text{cKO} BMDMs. Using unbiased ChIP sequencing of \( \text{PERK} \) WT and PSAT1\text{cKO} macrophages, the authors showed that \( \alpha \)-KG plays critical role in metabolic adaptation and \( \text{PERK}-\text{PSAT1} \) signaling facilitates an immunosuppressive M2 macrophage phenotype by regulating metabolic pathways and JMJD3 dependent histone demethylation \([6]\).

Given the profound effect of \( \text{PERK} \) signaling on M2 macrophage metabolic reprogramming and immunosuppressive function, few other studies examined whether inhibition of \( \text{PERK} \) signaling could elicit antitumor immune responses \([9,10]\). The results from these studies showed that UPR mediated \( \text{PERK} \) activation led to the transformation of myeloid cells into tumor-associated myeloid-derived suppressor cells. Further, \( \text{PERK} \) deletion reprogrammed tumor-myeloid cell-derived suppressor cells (MDSCs) into immunostimulatory cells, augmented \( \text{CD}^8^+ \) T-cell response and showed a synergistic response in combination with immunotherapy; suggesting \( \text{PERK} \) inhibition is a promising therapeutic strategy in cancer. Similarly, in this study Raines and colleagues examined the effect of the \( \text{PERK} \) inhibitor (GSK2656157) and PHGDH inhibitor (NCT-503) on B16-F10 melanoma xenografts and observed a significant reduction in tumor growth and number of immunosuppressive TAMs. Furthermore, treatment with the \( \text{PERK} \) inhibitor induced an antitumor response by increasing both \( \text{CD}^8^+ \) and \( \text{CD}^4^+ \) T-cell populations and the overall survival of melanoma bearing mice. Follow-up experiments revealed that combined treatment of the \( \text{PERK} \) inhibitor with immune checkpoint blockade/anti Programmed Cell Death Protein 1 (PD-1) immunotherapy enhance the antitumor efficacy in tumor bearing mice. These study results suggest that the \( \text{PERK} \) signaling inhibitor could be used to transform the immunosuppressive M2 macrophage phenotype to antitumor phenotype \([6]\).
In summary, Raines et al study uncovered PERK directed rewiring of metabolic circuits and epigenetic changes through the PERK-ATF4-PSAT1 axis as a novel mechanistic pathway in the modulation of TME. These exciting findings opened new avenues in the field of translational immunometabolism (Figure 1). Further, this study provided new directions in exploring the interplay between metabolomics and epigenetic changes, which will have wide implications to combat cancer and other metabolic and inflammatory diseases. Therefore, targeting PERK signaling could be used to modulate antitumor immune response by regulating immunosuppressive M2 macrophage metabolism. This strategy could also be used to target additional key proteins involved in metabolic reprogramming of the immune system in cancer. In addition, such therapies can also be extended for treating inflammatory diseases. Imperatively, future studies are needed to fill the large knowledge gap in the translation of preclinical study findings to clinical trials.

Conflicts of interest
The authors declare that they have no conflicts of interest.

Funding
This study is supported by the NIH grant 1R01CA262757-01A1 (RV), VA-1 101 BX004545-01 (RV), and MAYs Cancer Center grant P30 CA-54174.

Acknowledgments
We wish to thank Drs Gangadhara Reddy Sareddy, Suryavathi Viswanadhapalli, and Kristin A Altwegg for their thoughtful discussions and proof reading.

References
[1] Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer. 2014;14:581–97.
[2] Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2021;21:71–88.
[3] Batista A, Rodvold JJ, Xian S, et al. IRE1alpha regulates macrophage polarization, PD-L1 expression, and tumor survival. PLoS Biol. 2020;18:e3000687.
[4] Watanabe S, Alexander M, Misharin AV, et al. The role of macrophages in the resolution of inflammation. J Clin Invest. 2019;129:2619–28.
[5] Vitale I, Manic G, Cousseens LM, et al. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36–50.
[6] Raines LN, Zhao H, Wang Y, et al. PERK is a critical metabolic hub for immunosuppressive function in macrophages. Nat Immunol. 2022;23:431–45.
[7] Chakraborty P, Parikh RY, Choi S, et al. Carbon monoxide activates PERK-regulated autophagy to induce immunometabolic reprogramming and boost antitumor T-cell function. Cancer Res. 2022;82:1969–790.
[8] Gao X, Lee K, Reid MA, et al. Serine availability influences mitochondrial dynamics and function through lipid metabolism. Cell Rep. 2018;22:3507–20.
[9] Mohamed E, Sierra RA, Trillo-Tinoco J, et al. The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of STING signaling. Immunity. 2020;52:668–82.e7.
[10] Cao Y, Trillo-Tinoco J, Sierra RA, et al. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nat Commun. 2019;10:1280.

How to cite this article: Pratap UP, Vadlamudi RK. PERK promotes immunosuppressive M2 macrophage phenotype by metabolic reprogramming and epigenetic modifications through the PERK-ATF4-PSAT1 axis. Immunometabolism. 2022;4(3):e00007. doi: 10.1097/IN9.00000000000000007.